利培酮联合脑蛋白水解片对精神分裂症患者认知功能障碍的疗效

Efficacy on cognitive dysfunction in schizophrenia in risperidone and cerebroprotein hydrolysate treatment

目的探讨临床中利培酮与脑蛋白水解片联合治疗对精神分裂症患者认知功能障碍的影响。方法将90例精神分裂症患者采用随机数字表分为研究组和对照组,各45例。两组均给予利培酮治疗,研究组加用脑蛋白水解片治疗,疗程8周。采用威斯康星卡片分类测验(WCST)、韦氏成人智力量表(WAIS)和韦氏记忆量表(WMS)评估两组治疗效果。结果治疗前,两组的WCST,WMS和WAIS各项指标和评分比较差异无统计学意义(P>0.05);治疗后,两组的WCST中相关指标及WMS和WAIS的评分较治疗前有明显改善,且组间比较差异有统计学意义(P<0.05)。研究组不良反应发生率为11.0%,对照组不良反应发生率为17.7%,两组比较差异无统计学意义(P>0.05)。结论临床中对于精神分裂症患者实施利培酮与脑蛋白水解片联合治疗效果显著,能够有效地改善患者认知功能,提高治疗安全性。

Objective To investigate the clinical effects of risperidone combined cerebroprotein hydrolysate treated cognitive dys- function in schizophrenia. Methods 90 schizophrenia patients were randomly divided into the study group and the control group, and each group includes 45 patients. The control group were treated with risperidone , the study group 4 given risperidone combined cere- broprotein hydrolysate treatment , all treatment lasted for eight weeks. Both 2 groups were assessed with Wisconsin Card Sorting Test （WCST） , Wechsler Intelligence Scale（WAIS） and Wechsler Memory Scale（WMS）. Results On the baseline, there were no differ- ence between two groups in WCST, WMS and WAIS （ P 〉 0.05 ）. After 8 weeks treatment, both two groups performing better in WCST, WMS and WAIS, and the study group doing even better（P 〈0.05）. Adverse reactions of study group was 11.0 % while in the control group was 17.7%, which showed no significant difference （ P 〉 0.05 ）. Conclusion Risperidone combined cerebroprotein hydrolysate could effectively improve cognitive function and keep safe of schizophrenia patients.